Boehringer Ingelheim Steps Up to the Plate for Cystic Fibrosis Patients

Germany’s Boehringer Ingelheim is taking its commitment to patients with cystic fibrosis to the next level. Choosing to exercise its options with a group of research and development partners, the pharma giant will accelerate a promising new C.F. gene therapy.